The Leukemia & Lymphoma Society Canada Names Christopher Barry its New President

TORONTO, July 4, 2013 /CNW/ - The Leukemia & Lymphoma Society Canada® (LLSC) has named Christopher Barry, former President of Starlight Children's Foundation, as its new President, effective July 8, 2013.

Barry will steward LLSC in its efforts to find cures and ensure access to therapies for all blood cancer patients in Canada.

"Christopher Barry has a proven track record of achievement in building relationships and collaboration with potential donors, internal and external stakeholders, the media, employees and the public to the benefit of the organizations he has led, and we look forward to the leadership skills he will bring to LLSC," said Gilles Legault, Chairman of LLSC's Board of Directors .

Most recently Barry was President of Starlight Children's Foundation, Canada's largest children's charity, which grants wishes to seriously ill children through in-hospital and out of hospital programs. He previously served with great track-record as interim Chief Executive Officer forCanada's largest humane society. His background also includes extensive private sector experience in senior roles in North America and Asia.

Barry earned a master's degree in international trade from Johns Hopkins University School of Advanced International Studies in Washington, D.C. He is a graduate of the Royal Bank's Advanced Account Management Program (one of only fifteen executives selected each year for a 12 month term).

About The Leukemia & Lymphoma Society Canada

The Leukemia & Lymphoma Society of Canada® (LLSC) is Canada's largest voluntary health agency dedicated to blood cancer. The LLSC mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLSC funds lifesaving blood cancer research across Canada and provides free information and support services.

Founded in 1955, LLSC has offices across Canada. To learn more, visit www.llscanada.org or contact 1-866-600-0567.

Charitable Business No. 10762 3654 RR0001. www.llscanada.org.

SOURCE The Leukemia & Lymphoma Society of Canada

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.